EUVIMEDEUVIMED entdecken
Open Access

Development of an Optimized CXCR4-Targeting Theranostic Pair

Daniel Kwon, Ingrid Bloise, Zhengxing Zhang, Nadine Colpo, Ryan Wilson, Ruiyan Tan, Helen Merkens, Jutta Zeisler, Joseph Lau, Kuo-Shyan Lin, François Bénard

Journal of Nuclear Medicine · 2026-05 · 67 (5) · 773-779

DOI: 10.2967/jnumed.125.269933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.01.2026. Verfasst von Daniel Kwon und 10 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer Research Institute, Vancouver, British Columbia, Canada; and. Hauptthemen laut MEDLINE: Receptors, CXCR4, Theranostic Nanomedicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We developed a new C-X-C chemokine receptor 4 (CXCR4)-targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure-activity relationship studies of LY2510924.

Methods

Candidate inhibitors were designed on the basis of structure-activity studies and synthesized using solid-phase techniques, and their CXCR4 binding was assessed using a cell-based assay. An optimized cyclic peptide sequence was modified with a Lys-cysteic acid linker and DOTA chelator to make BL34. Other analogs possessing ornithine or diaminopimelic acid linkers were also synthesized and assessed. All radiotracers were assessed in mice engrafted with a mantle cell lymphoma model (Z138) via PET/SPECT imaging and biodistribution studies. Therapeutic efficacy of [177Lu]Lu-BL34 was assessed in Z138-engrafted mice with groups of 30 and 60 MBq and a control.

Results

The optimized cyclic peptide showed a 3-fold improvement in CXCR4 binding compared with that of LY2510924. [68Ga]Ga-BL34 showed high imaging contrast for the tumor at 1 and 2 h after injection. Biodistribution studies confirmed these results, with an uptake of 15.1 ± 3.1 %ID/g in the tumor at 1 h after injection and primarily renal excretion with a kidney uptake of 2.4 ± 0.4 %ID/g. SPECT imaging of [177Lu]Lu-BL34 showed similar results, with rapid renal excretion of [177Lu]Lu-BL34 from nontarget organs and relatively high uptake in tumors up to 72 h after injection. Biodistribution studies confirmed high tumor uptake at all time points, with low uptake across all nontarget organs. Blocking studies with LY2510924 further confirmed specificity. Therapy studies showed dose-dependent survival benefit with [177Lu]Lu-BL34 treatment, with metastatic recurrence in the treatment groups. Changing the side chain length at the linker attachment site did not affect the biodistribution or tumor uptake.

Conclusion

We report a new CXCR4-targeting pharmacophore that can be used as a radiotheranostic. [68Ga]Ga-BL34 and [177Lu]Lu-BL34 showed excellent imaging and therapeutic properties in preclinical studies and are promising candidates for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Theranostic NanomedicineAnimalsMiceTissue DistributionPeptides, CyclicHumansCell Line, TumorGallium RadioisotopesLutetiumRadioisotopesRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonStructure-Activity RelationshipFemale

Stichwörter der Autor:innen

CXCR4PETSPECTchemokine receptorsradiotheranostics

Substanzen

Receptors, CXCR4Peptides, CyclicGallium RadioisotopesLY2510924LutetiumGallium-68RadioisotopesRadiopharmaceuticalsLutetium-177

Autor:innen und Institutionen

  • BC Cancer Research Institute, Vancouver, British Columbia, Canada; and.
  • Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
  • BC Cancer Research Institute, Vancouver, British Columbia, Canada; and fbenard@bccrc.ca.

Zitieren

APA

Kwon, D., Bloise, I., Zhang, Z., Colpo, N., Wilson, R., Tan, R., Merkens, H., Zeisler, J., Lau, J., Lin, K. S., & Bénard, F. (2026). Development of an Optimized CXCR4-Targeting Theranostic Pair. Journal of Nuclear Medicine, 67(5), 773-779. https://doi.org/10.2967/jnumed.125.269933

Vancouver

Kwon D, Bloise I, Zhang Z, Colpo N, Wilson R, Tan R, et al. Development of an Optimized CXCR4-Targeting Theranostic Pair. Journal of Nuclear Medicine. 2026;67(5):773-779. doi:10.2967/jnumed.125.269933

BibTeX
@article{Kwon2026,
  author = {Kwon, Daniel and Bloise, Ingrid and Zhang, Zhengxing and Colpo, Nadine and Wilson, Ryan and Tan, Ruiyan and Merkens, Helen and Zeisler, Jutta and Lau, Joseph and Lin, Kuo-Shyan and Bénard, François},
  title = {Development of an Optimized CXCR4-Targeting Theranostic Pair},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {773--779},
  doi = {10.2967/jnumed.125.269933}
}
Kostenlos starten →